Moving closer to Epstein-Barr virus vaccine to prevent mono, some cancers
10/15/2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system. EBV causes infectious mononucleosis and cancers such as Hodgkin's lymphoma and nasopharyngeal carcinoma, which is the most common cancer in China, as well as opportunistic cancers in people with weakened immune systems...
Predictiing outcome in prostate cancer by measuring change in circulating tumor cells
10/15/2013
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague...
Ovarian cancer patients may benefit from targeted treatment plus chemotherapy
10/15/2013
Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows...
Artificial antigen-presenting cells bolster the body's defense against cancer
10/15/2013
Researchers at Johns Hopkins have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice...
4 genetic variants linked to esophageal cancer and Barrett's esophagus identified
10/15/2013
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, a condition called Barrett's esophagus. The findings, by corresponding author Thomas L. Vaughan, M.D., M.P.H...
Gene mutation linked to low-risk bladder cancer
10/15/2013
An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. Their findings are reported online in Nature Genetics. The investigators identified STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not spread...
Moving closer to Epstein-Barr virus vaccine to prevent mono, some cancers
10/15/2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system. EBV causes infectious mononucleosis and cancers such as Hodgkin's lymphoma and nasopharyngeal carcinoma, which is the most common cancer in China, as well as opportunistic cancers in people with weakened immune systems...
Resveratrol could help treat melanoma and other cancers
10/15/2013
A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer...
Cell growth discovery has implications for targeting cancer
10/15/2013
The way cells divide to form new cells - to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning - is controlled in previously unsuspected ways UC San Francisco researchers have discovered. The findings, they said, may lead to new ways to fight cancer...
More secrets of glioblastoma multiforme exposed by the Cancer Genome Atlas
10/15/2013
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first. TCGA ganged up on glioblastoma multiforme (GBM), the most common and lethal of brain tumors, with more than 100 scientists from 14 institutions tracking down the genomic abnormalities that drive GBM...